Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.
|
| Abstract |
<title/> Adult patients with primary immune thrombocytopenia requiring first-line treatment typically receive corticosteroids, which are associated with low response rates and many potential side effects. In a retrospective analysis of two 6-month, placebo-controlled, phase III trials, corticosteroid use decreased from 30 to 26% among patients treated with the novel thrombopoietin-mimetic romiplostim (n = 83) and remained above 30% for placebo-treated patients (n = 42). Moreover, compared to placebo, patients were spared 7 weeks of corticosteroid treatment for every 100 weeks of romiplostim treatment. Thereafter, corticosteroid use continued to decrease significantly, from 35 to 20%, in patients treated with romiplostim for up to 3 years in an open-label extension study (n = 101), and patients were spared a further 8 weeks of corticosteroid treatment for each additional 100 weeks of romiplostim treatment. Such reductions in corticosteroids may improve health-related quality of life in patients with primary immune thrombocytopenia.
|
|---|---|
| Authors | Marc Michel, Peter A W te Boekhorst, Ann Janssens, Ingrid Pabinger-Fasching, Miguel A Sanz, Kun Nie, Georg Kreuzbauer |
| Journal | Hematology (Amsterdam, Netherlands) (Hematology) Vol. 16 Issue 5 Pg. 274-7 (Sep 2011) ISSN: 1607-8454 [Electronic] England |
| PMID | 21902890 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!